摘要
慢性阻塞性肺疾病(COPD)是呼吸系统的常见病和多发病。现通过对丙酸氟替卡松/沙美特罗(ICS/LABA)在COPD治疗中的作用机制及研究进展进行综述,阐述沙美特罗/丙酸氟替卡松联合治疗可显著降低COPD患者呼吸道炎症、显著改善1秒最大呼气量(FEV1)、FEV1减退率、急性加重次数及生活质量,降低COPD患者所有原因病死率,而且耐受性良好,是COPD患者有效、安全的治疗方法。
Chron ic obstructive pu lmonary d isease is a common and frequently occurred resp iratory d is-ease,th is article reviews the m echan ism and the progress of treating COPD w ith ICS /LABA（Salm eterol/Flu-ticasone）,and it states that comb ination therapy w ith Salm eterol/Fluticasone sign ificantly reduce airway in-flammatory of COPD,improve FEV1 and FEV1 decline rate,reduce the frequency of exacerbations,improve the quality of life,reduce all cause mortality of COPD patients,and it has good tolerance.Therefore,Salm et-erol/Fluticasone comb ination therapy is an effective and safe treatm ent of patients w ith COPD.
出处
《医学综述》
2011年第8期1212-1214,共3页
Medical Recapitulate
